Respiratory

Solitary pulmonary nodule: Fleischner Society follow-up

Clinical Overview and When to Suspect Solitary Pulmonary Nodule

— Lesions >30 mm are termed masses and are presumed malignant until proven otherwise — these do NOT follow Fleischner pathways.

— Subsolid nodules are subdivided into pure ground-glass nodules (GGN) and part-solid nodules (mixed GGN with solid component).

— Incidentally detected on ~1–2 per 1,000 chest radiographs and on up to 30% of chest CTs.

— Malignancy prevalence varies: <1% for nodules <5 mm; up to 15–20% for 8–20 mm; ~50% for >20 mm in smokers >50.

— Most benign causes: infectious granuloma (histoplasmosis, TB, coccidioides), hamartoma, intrapulmonary lymph node.

— Most common malignancies: primary lung adenocarcinoma, squamous cell carcinoma, solitary metastasis (colon, breast, renal, melanoma, sarcoma).

— Apply to: incidentally detected nodules in patients ≥35 years old with no known malignancy and not undergoing lung cancer screening.

— Do NOT apply to: patients in formal lung cancer screening programs (use Lung-RADS instead), patients with known cancer (oncologic surveillance), immunocompromised hosts, or those <35 years (infection/benign etiology dominates).

— Patient: age >60, current/heavy smoking, family history of lung cancer, asbestos/radon exposure, emphysema, pulmonary fibrosis.

— Nodule: upper lobe location, spiculated margins, larger size, part-solid morphology.

Board pearl: The first decision tree fork on Step 3 is "Is this a screening CT or an incidental finding?" — Lung-RADS governs screening; Fleischner governs incidental nodules. Mixing the two is a classic distractor.

Definition: A solitary pulmonary nodule (SPN) is a single, rounded opacity ≤30 mm in diameter, surrounded by aerated lung, without associated atelectasis, hilar adenopathy, or pleural effusion.

Epidemiology and pretest probability:

When to invoke Fleischner Society guidelines (2017 update):

Risk modifiers that push toward shorter intervals/biopsy:

Presentation Patterns and Key History

— Symptomatic nodules (hemoptysis, weight loss, postobstructive pneumonia) suggest malignancy or active infection and warrant tissue diagnosis rather than surveillance imaging.

— Tobacco: pack-years, current vs former, years since quit. ≥30 pack-years = high risk by Fleischner schema.

— Occupational/environmental: asbestos (shipyard, insulation, brake mechanic), radon (basement dweller in granite-rich regions), silica, diesel exhaust, secondhand smoke.

— Prior malignancy: any solid tumor, especially head/neck, breast, colon, renal, melanoma, sarcoma — converts workup from "Fleischner" to "metastatic surveillance."

— Infectious exposures: travel/residence in Ohio/Mississippi River valleys (histoplasmosis), southwestern US (coccidioidomycosis), TB contacts, HIV status, transplant or biologic immunosuppression.

— Family history: first-degree relative with lung cancer (especially if diagnosed <60) ≈ 2x risk.

— Symptoms: cough, hemoptysis, weight loss, night sweats, fevers — any positive symptom moves you toward tissue diagnosis.

— Stability for ≥2 years (solid nodule) or ≥5 years (subsolid nodule) generally confirms benignity and ends workup.

— Document interval growth: doubling time <30 days suggests infection/inflammation; >450 days suggests benignity; 30–400 days is the malignancy window.

Step 3 management: Before ordering any new CT, request and review outside prior imaging (PACS, CD upload, release of records). On CCS, this is the high-value, low-cost action that often closes the case without further radiation or biopsy.

Typical scenario: SPN is asymptomatic and discovered incidentally on imaging obtained for unrelated reasons — preop chest x-ray, CT for trauma, CT pulmonary angiogram for chest pain, coronary calcium scoring CT, or cardiac MRI scout images.

History elements to extract (these directly modify Fleischner risk category — low vs high risk):

Look for prior imaging — the single most cost-effective maneuver:

Physical Exam Findings and Functional Assessment

— Vital signs: unexplained tachycardia, low-grade fever, weight loss documented across visits → suggests malignancy or infection over benign granuloma.

— HEENT/neck: supraclavicular or cervical lymphadenopathy (Virchow node, scalene nodes) — if palpable, biopsy the node first (lowest-risk, highest-yield tissue source, may also stage as N3).

— Pulmonary: localized wheezing (endobronchial lesion), focal crackles, dullness suggesting effusion. Clubbing raises suspicion for lung cancer, chronic suppurative disease, or interstitial lung disease.

— Cardiac: new murmur or pericardial rub may indicate metastatic involvement.

— Abdomen: hepatomegaly or palpable mass suggesting metastatic burden or alternate primary.

— Skin: melanoma scars, café-au-lait (neurofibromatosis with pulmonary metastases), tylosis, dermatomyositis (paraneoplastic).

— Neuro: focal deficits → brain metastasis; Horner syndrome (ptosis, miosis, anhidrosis) → Pancoast/superior sulcus tumor.

— Musculoskeletal: hypertrophic pulmonary osteoarthropathy — clubbing + periostitis of long bones, strongly associated with NSCLC.

— Document ECOG performance status, exercise tolerance (stairs/blocks), home oxygen use, baseline dyspnea.

— Poor performance status (ECOG ≥3) may itself argue against aggressive biopsy or resection regardless of Fleischner category.

Key distinction: A truly incidental, asymptomatic SPN in a patient with a normal exam follows Fleischner surveillance. Any focal exam abnormality (lymphadenopathy, Horner, clubbing, weight loss) bypasses Fleischner timing and triggers expedited tissue diagnosis — usually PET/CT followed by biopsy of the most accessible high-FDG-avid site.

General principle: The physical exam in SPN is overwhelmingly normal; an abnormal exam shifts the case away from "incidental SPN follow-up" and toward "symptomatic pulmonary lesion requiring directed workup."

Focused exam by system:

Functional/performance assessment (gates future interventions):

Diagnostic Workup — Initial Imaging Characterization

— Contrast is generally not required for nodule characterization; reserve for suspected vascular lesion (AVM), mediastinal staging, or concurrent infection workup.

— Reconstruct in axial, coronal, sagittal planes; review with lung and mediastinal windows.

— Size: report average of long- and short-axis diameter on the single image showing the largest dimension, rounded to nearest mm. Volume measurement (if available) is preferred for subsolid nodules.

— Attenuation: solid (soft-tissue density obscuring vessels), part-solid (GGN + solid component ≥3 mm), pure ground-glass (hazy increased attenuation, vessels still visible).

— Margin: smooth (benign-leaning), lobulated, spiculated (sunburst → malignancy), or "corona radiata."

— Internal features: calcification pattern, fat, cavitation, air bronchograms.

— Diffuse, central, laminated/concentric, "popcorn."

— Popcorn calcification + fat density = pulmonary hamartoma (pathognomonic).

— Granulomas: central or diffuse calcification, often from prior histoplasmosis/TB.

— Perifissural location with triangular/oval shape and smooth margins → intrapulmonary lymph node (very common, requires no follow-up).

— Macroscopic fat → hamartoma or lipoid pneumonia.

Board pearl: A perifissural nodule <10 mm with the typical triangular morphology is an intrapulmonary lymph node and is exempt from Fleischner surveillance — recognizing this saves the patient years of follow-up scans.

Chest CT with thin sections (≤1.5 mm) without contrast is the foundational study for any SPN identified on chest radiograph or non-dedicated CT.

Key CT descriptors that drive Fleischner categorization:

Benign calcification patterns (essentially exclude malignancy, end workup):

Calcification patterns suspicious for malignancy: eccentric, stippled, punctate, or amorphous.

Other benign-favoring features:

Initial labs: generally minimal for asymptomatic SPN. Consider CBC, basic metabolic panel, and HIV testing if infectious cause suspected. Tumor markers (CEA, CYFRA 21-1) have no role in SPN workup.

Diagnostic Workup — Advanced and Confirmatory Studies

— High FDG uptake (SUVmax >2.5) → suspicious; proceed to biopsy or resection.

— Low uptake → favors benign, but does not exclude malignancy.

— False negatives: carcinoid tumors, adenocarcinoma in situ (former BAC), lesions <8 mm, ground-glass nodules.

— False positives: active granulomas (TB, histoplasmosis, sarcoid), rheumatoid nodules, abscess, recent biopsy site.

— PET is not recommended for nodules <8 mm or pure GGN regardless of size.

— CT-guided transthoracic needle biopsy (TTNB): best for peripheral lesions; sensitivity ~90%; pneumothorax risk ~15–25%, chest tube ~5%.

— Bronchoscopy with EBUS/navigational bronchoscopy: best for central lesions, lesions with bronchus sign, and concurrent mediastinal staging via EBUS-TBNA.

— Surgical biopsy/wedge resection (VATS): when pretest probability is high and lesion is amenable — both diagnostic and therapeutic.

— Mayo Clinic model and Brock University model estimate malignancy probability from age, smoking, prior cancer, size, spiculation, upper lobe location.

— Low probability (<5%) → surveillance; intermediate (5–65%) → PET or biopsy; high (>65%) → surgical resection (skip biopsy if surgical candidate).

— High-probability nodule in good surgical candidate.

— Biopsy access difficult or prior nondiagnostic attempt.

— Patient preference for definitive management.

Step 3 management: For an 8 mm solid nodule, intermediate risk — order PET/CT first. If PET-avid → biopsy or resection. If PET-cold → resume Fleischner CT surveillance at 3 months, then 9–12, then 18–24 months. Do not jump straight to surgery without staging in intermediate-risk lesions.

PET/CT (FDG-PET): indicated for solid nodules ≥8 mm in patients with intermediate pretest probability for malignancy.

Tissue sampling modalities (choose based on location, size, comorbidities):

Risk-prediction tools to stratify before biopsy:

When to skip biopsy and go to resection:

Fleischner 2017 — Solid Nodule Surveillance Algorithm

— Low risk: minimal/no smoking history, no other risk factors.

— High risk: heavy smoker, prior asbestos/radon, family history, emphysema/fibrosis, upper lobe, spiculated.

— <6 mm (<100 mm³): Low risk → no routine follow-up. High risk → optional CT at 12 months.

— 6–8 mm (100–250 mm³): Low risk → CT at 6–12 months, consider CT at 18–24 months. High risk → CT at 6–12 months, then 18–24 months.

— >8 mm (>250 mm³): Consider CT at 3 months, PET/CT, or tissue sampling — risk category does not change this; decision driven by Mayo/Brock probability.

— <6 mm: Low risk → no routine follow-up. High risk → optional CT at 12 months.

— 6–8 mm or >8 mm: CT at 3–6 months, then 18–24 months, regardless of risk.

— Measurements are average of long and short axis; round to mm.

— "No routine follow-up" does not mean ignore — document and re-image if symptoms develop.

— If nodule grows or develops a solid component at any interval → biopsy or resection.

— Growth defined as ≥2 mm increase in average diameter or new solid component.

CCS pearl: On a CCS case with an incidental 7 mm solid right upper lobe nodule in a 62-year-old former smoker, the correct next step is chest CT in 6–12 months, not PET, not biopsy. Ordering PET for a sub-8 mm nodule is a classic over-management trap.

Apply per Fleischner 2017 (adults ≥35, incidental, non-screening, non-immunocompromised, no known cancer). Categorize by size, number (single vs multiple), and risk (low vs high).

Risk stratification:

Solid SINGLE nodule:

Solid MULTIPLE nodules (dominant nodule guides):

Important caveats:

Endpoint of surveillance: stability for 2 years for solid nodules confirms benignity → stop scanning.

Fleischner 2017 — Subsolid Nodule Surveillance Algorithm

— <6 mm: no routine follow-up.

— ≥6 mm: CT at 6–12 months to confirm persistence, then every 2 years until 5 years.

— <6 mm: no routine follow-up (rare and usually transient inflammatory).

— ≥6 mm: CT at 3–6 months to confirm persistence. If unchanged and solid component remains <6 mm, annual CT for 5 years. If solid component ≥6 mm → highly suspicious → PET/CT, biopsy, or resection.

— <6 mm: CT at 3–6 months. If stable, consider CT at 2 and 4 years.

— ≥6 mm: CT at 3–6 months. Subsequent management based on most suspicious nodule (largest solid component or growing).

— A new subsolid nodule on first CT may be infectious/inflammatory — that is why the 3–6 month confirmatory scan exists. Transient = no further follow-up.

— Persistent pure GGN ≥6 mm that remains pure ground-glass is most often AIS or MIA — indolent, but warrants long-term surveillance.

— Development of a solid component within a previously pure GGN signals invasive transformation → resection.

Board pearl: A persistent pure GGN in a never-smoker woman is the classic adenocarcinoma in situ vignette — slow doubling time, indolent course, follow with annual low-dose CT for 5 years, resect if it develops a solid component.

Why subsolid nodules behave differently: pure GGNs and part-solid nodules often represent the adenocarcinoma spectrum — atypical adenomatous hyperplasia (AAH) → adenocarcinoma in situ (AIS) → minimally invasive adenocarcinoma (MIA) → invasive adenocarcinoma. They grow slowly (doubling time often >400 days) and require longer surveillance — up to 5 years.

Pure ground-glass nodule (GGN), single:

Part-solid nodule, single:

Multiple subsolid nodules:

Critical interpretation points:

PET/CT is NOT useful for pure GGN or small part-solid nodules — high false-negative rate due to low metabolic activity of indolent adenocarcinoma spectrum.

Procedural Management — Biopsy and Resection

— Solid nodule >8 mm with intermediate-to-high probability of malignancy.

— Any nodule with documented growth ≥2 mm or new/enlarging solid component.

— Part-solid nodule with solid component ≥6 mm.

— PET-avid nodule (SUV >2.5) in appropriate clinical context.

— Best for peripheral nodules >1 cm within 3 cm of pleura.

— Diagnostic yield 80–95%; specificity for malignancy ~98%.

— Complications: pneumothorax (15–25%, ~5% requiring chest tube), pulmonary hemorrhage/hemoptysis (5–10%), air embolism (rare).

— Contraindications: severe COPD/bullous emphysema, uncorrectable coagulopathy, single lung, pulmonary hypertension, inability to lie still or breath-hold.

— Standard flexible bronchoscopy yield poor (<30%) for peripheral lesions.

— EBUS (radial probe) and electromagnetic navigational bronchoscopy improve yield to 65–75% for peripheral nodules.

— Linear EBUS-TBNA simultaneously samples mediastinal nodes for staging — preferred when both diagnosis and N-staging needed.

— Definitive when probability of malignancy is high (>65%) or biopsy nondiagnostic.

— Frozen section guides intraoperative conversion to lobectomy with mediastinal lymph node dissection if NSCLC confirmed and patient tolerates.

— Stereotactic body radiotherapy (SBRT) is an alternative for medically inoperable stage I NSCLC.

— Pulmonary function tests (FEV1, DLCO) before any planned resection.

— Cardiac risk stratification per ACC/AHA guidelines for non-cardiac surgery.

— Smoking cessation ≥4 weeks preop reduces pulmonary complications.

Step 3 management: In an intermediate-risk 1.2 cm spiculated upper lobe nodule with PET SUV 6, in a fit 68-year-old — proceed to surgical wedge resection with frozen section and possible lobectomy + mediastinal LN sampling, rather than separate needle biopsy first.

When to proceed to tissue:

CT-guided transthoracic needle biopsy (TTNB):

Bronchoscopy:

Surgical management (VATS wedge resection):

Pre-procedure workup:

Special Populations — Elderly and Renal/Hepatic Impairment

— Higher baseline malignancy prevalence in incidental SPN (15–25%).

— However, competing comorbidities (cardiopulmonary disease, frailty) often dominate prognosis; aggressive workup may not change life expectancy.

— Use shared decision-making: discuss life expectancy estimates and patient values before initiating Fleischner surveillance.

— If patient has life expectancy <5 years from comorbidities, consider forgoing surveillance entirely — a Fleischner-positive nodule that takes 3 years to declare itself is unlikely to alter outcome.

— Cumulative radiation exposure is less of a concern in elderly but anxiety, false positives, and procedure complications are real harms.

— Fleischner CT is non-contrast — no contrast-induced nephropathy risk.

— PET/CT uses FDG, renally cleared; no contraindication, but hydration encouraged. CT contrast in dedicated chest CT is rarely required.

— If contrast needed (e.g., for staging CT), use iso-osmolar contrast, pre/post hydration, hold metformin and nephrotoxins per institutional protocol if eGFR <30.

— No direct impact on Fleischner imaging.

— Affects drug metabolism and surgical candidacy: child-Pugh B/C cirrhosis dramatically increases perioperative mortality for lung resection.

— Coagulopathy from liver disease increases bleeding risk of TTNB — correct INR and platelets before biopsy.

— A vigorous 82-year-old with ECOG 0 may be a better surgical candidate than a deconditioned 65-year-old.

— Use frailty indices (Clinical Frailty Scale, "timed up and go") rather than age alone.

Key distinction: Fleischner surveillance is age-adjusted by life expectancy, not by chronologic cutoff. The guideline applies starting at age 35; the upper bound is determined by expected longevity ≥5–10 years — beyond which surveillance benefit evaporates and may cause net harm through procedure complications and anxiety.

Elderly (age >75):

Renal impairment:

Hepatic impairment:

Functional status overrides chronologic age:

Special Populations — Pregnancy, Pediatrics, Immunocompromised, Known Cancer

— Fleischner does not specifically address pregnancy; imaging decisions follow general radiation principles.

— Chest CT delivers fetal dose ~0.01–0.66 mGy, well below the 50 mGy teratogenic threshold; defer if surveillance can wait until postpartum.

— For symptomatic or growing nodule, diagnostic workup proceeds with appropriate shielding; do not delay malignancy diagnosis.

— MRI without gadolinium is an alternative for further characterization in some cases.

— Fleischner explicitly excludes patients <35 because infectious/inflammatory etiology dominates and lung cancer is rare.

— Workup directed at granulomatous infection (histoplasmosis, coccidioides, TB), congenital lesions (bronchogenic cyst, sequestration, CCAM), and rare malignancies (pleuropulmonary blastoma, carcinoid).

— Children with prior malignancy (osteosarcoma, Wilms, Ewing) → metastasis surveillance protocol, not Fleischner.

— Fleischner does not apply.

— Pulmonary nodules in this group most commonly represent opportunistic infections — invasive aspergillosis (halo sign, air crescent), nocardia, cryptococcus, mycobacteria, PJP, septic emboli.

— Lower threshold for early bronchoscopy with BAL and biopsy.

— Empiric antimicrobials may be initiated while workup proceeds.

— Use oncologic surveillance pathways, not Fleischner.

— New nodules are presumed metastatic until proven otherwise — biopsy or short-interval imaging (typically 6–8 weeks) driven by primary tumor type and treatment plan.

— Solitary lung lesion in patient with prior cancer may be second primary lung cancer (especially head/neck, breast) rather than metastasis — tissue diagnosis often required because it changes therapy.

Board pearl: "Fleischner does not apply" is the right answer for: known cancer, immunocompromised, age <35, and lung-cancer-screening CTs (use Lung-RADS). Recognizing which patients fall outside the algorithm is itself a high-yield testable point.

Pregnancy:

Pediatrics (<35 years):

Immunocompromised patients (HIV with low CD4, solid organ transplant, hematologic malignancy, chronic high-dose steroids, biologics):

Patients with known malignancy:

Complications and Adverse Outcomes

— Progression to invasive lung cancer with metastasis (brain, bone, liver, adrenal).

— Postobstructive pneumonia, atelectasis, hemoptysis.

— Paraneoplastic syndromes: SIADH (small cell), Cushing (small cell carcinoid), hypercalcemia of malignancy (squamous, PTHrP), Lambert-Eaton, hypertrophic osteoarthropathy.

— Cumulative radiation: each chest CT ~2–7 mSv. Multiple scans over years add up — relevant especially in young patients.

— Incidental findings cascade: thyroid nodules, adrenal incidentalomas, hepatic cysts, coronary calcium — each potentially generating further workup.

— Patient anxiety: "scanxiety" is well-documented; informed consent should mention psychological burden.

— TTNB: pneumothorax (15–25%; chest tube in ~5%), hemoptysis, air embolism (rare but catastrophic), tumor seeding along needle tract (very rare).

— Bronchoscopy: pneumothorax (1–5%), bleeding, hypoxemia, post-procedure fever.

— Surgical wedge/lobectomy: perioperative mortality 1–3%, prolonged air leak, atrial fibrillation, pneumonia, chronic post-thoracotomy pain.

— False reassurance: missed early malignancy due to misclassification (e.g., labeling part-solid nodule as pure GGN, undercounting size).

— Overdiagnosis: indolent AIS/MIA detected and resected that may never have caused harm — especially in elderly.

— Loss to follow-up: the single most common safety failure — incidental nodule noted in radiology report but not communicated to patient or PCP.

— Use standardized reporting templates (Fleischner language) in radiology reports.

— Closed-loop communication systems — automated alerts to PCP, patient portal notifications.

— Nodule tracking registries within EHRs.

Step 3 management: When a hospitalized patient has an incidental SPN noted on a CT obtained for another reason, document the finding in the discharge summary, communicate to the PCP explicitly, and arrange the Fleischner-appropriate follow-up CT — closing this loop is a tested patient-safety competency.

Complications of the nodule itself (if malignant):

Complications of surveillance imaging:

Complications of biopsy:

Diagnostic errors:

Mitigation strategies:

When to Escalate Care — Specialist Referral and Inpatient Triage

— Nodule >8 mm with intermediate probability requiring PET/biopsy decision.

— Multiple nodules with uncertain etiology.

— Subsolid nodules requiring longitudinal multidisciplinary management.

— Patient with significant comorbid lung disease (severe COPD, IPF) where workup risk-benefit is complex.

— Need for EBUS or navigational bronchoscopy.

— High pretest probability (>65%) of malignancy.

— Biopsy nondiagnostic but suspicion remains.

— Growth on surveillance imaging.

— Patient prefers definitive resection over surveillance/biopsy.

— Massive hemoptysis (>200 mL/24 hr) — admit, secure airway, bronchoscopy ± bronchial artery embolization.

— Postobstructive pneumonia with sepsis.

— Cord compression, SVC syndrome, or new neurologic deficits — admit for staging and emergent oncologic intervention.

— Pneumothorax after TTNB with hemodynamic compromise or >2 cm → chest tube.

— Initial recognition and triage of incidental finding.

— Coordinating Fleischner surveillance.

— Tracking imaging timelines and ensuring patient adherence.

— Risk-factor modification (smoking cessation, occupational exposure counseling).

CCS pearl: A patient with an 8 mm spiculated upper lobe nodule and 40 pack-year smoking history — appropriate CCS sequence: outpatient PET/CT, pulmonology consultation, smoking cessation counseling with varenicline or combination NRT, and influenza/pneumococcal vaccination, all before invasive workup.

Most SPN workup is outpatient. Inpatient escalation is uncommon and triggered by specific findings.

Pulmonology referral indicated when:

Thoracic surgery referral indicated when:

Multidisciplinary tumor board for confirmed or strongly suspected malignancy — pulmonary, thoracic surgery, radiation oncology, medical oncology, radiology, pathology.

Interventional radiology for image-guided biopsy planning, especially difficult-access lesions.

Inpatient triage / urgent evaluation if:

Primary care role:

Key Differentials — Pulmonary Same-Category Causes

— Adenocarcinoma (most common): peripheral, often part-solid or pure GGN; associated with never-smokers and women; EGFR/ALK/KRAS mutations.

— Squamous cell carcinoma: central or cavitary, smoking-associated, hypercalcemia (PTHrP).

— Small cell carcinoma: typically central with bulky adenopathy; rarely presents as true SPN.

— Large cell neuroendocrine carcinoma: aggressive, peripheral.

— Carcinoid tumor: central or peripheral; well-defined, often endobronchial; PET-negative due to low FDG uptake — classic false-negative.

— Solitary pulmonary metastasis from colon, breast, renal cell, melanoma, sarcoma, head/neck.

— Typically smooth-bordered, lower lobe (blood-flow distribution).

— Solitary metastasis from sarcoma → consider metastasectomy if controlled primary.

— Histoplasmosis: Mississippi/Ohio River valleys, often calcified granulomas.

— Coccidioidomycosis: southwestern US; nodule may cavitate ("coin lesion").

— Tuberculosis: upper lobe predilection, cavitation, calcified Ghon lesion.

— Cryptococcosis, blastomycosis, aspergilloma (mycetoma within preexisting cavity).

— Nocardia, Rhodococcus in immunocompromised.

— Bacterial abscess: thick-walled cavity with air-fluid level.

— Round pneumonia (more common in pediatrics).

— Septic emboli (multiple, peripheral, cavitating — IV drug use, endocarditis).

— Echinococcus (hydatid cyst): thin-walled cyst, endemic regions.

— Hamartoma: popcorn calcification + fat — pathognomonic.

— Chondroma, leiomyoma, lipoma (rare).

Key distinction: A cavitary nodule with thick irregular walls (>15 mm) strongly suggests squamous cell carcinoma; thin-walled cavities (<4 mm) suggest benign processes (bullae, infectious cyst). Wall thickness is a fast bedside heuristic on CT.

Malignant — primary lung:

Malignant — metastatic:

Infectious — granulomatous:

Infectious — non-granulomatous:

Benign neoplasms:

Key Differentials — Non-Neoplastic and Other-Category Causes

— Pulmonary arteriovenous malformation (AVM): smooth, lobulated, with feeding artery and draining vein — classic in hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu); risk of paradoxical embolism, stroke, brain abscess; treat with coil embolization.

— Pulmonary artery aneurysm.

— Pulmonary infarct: wedge-shaped, peripheral, may resolve to nodule (Hampton hump initially).

— Rheumatoid nodule: subpleural, in patients with seropositive RA; may cavitate; Caplan syndrome when combined with pneumoconiosis.

— Granulomatosis with polyangiitis (GPA): multiple cavitating nodules, hematuria, sinus disease, c-ANCA/PR3 positive.

— Sarcoidosis: typically diffuse with hilar adenopathy, but solitary "sarcoid nodule" exists.

— IgG4-related disease.

— Bronchogenic cyst (fluid-density, mediastinal/parenchymal).

— Pulmonary sequestration (usually lower lobe, systemic arterial supply from aorta).

— Congenital pulmonary airway malformation (CPAM).

— Mucoid impaction, post-radiation fibrosis, retained surgical material.

— Talc granulomatosis in IV drug users (multiple small nodules).

— Drug-induced pneumonitis (amiodarone, methotrexate, nitrofurantoin, immune checkpoint inhibitors) — usually diffuse but can be nodular.

— Nipple shadow, skin lesions, rib fractures, bone islands, pleural plaques (asbestos).

— Always confirm with thin-section CT before initiating workup on chest x-ray alone.

Board pearl: Multiple cavitating nodules + hematuria + sinusitis is GPA until proven otherwise — order c-ANCA/PR3, urinalysis with microscopy, and consider renal biopsy; this is not a Fleischner case.

Vascular:

Inflammatory/autoimmune:

Congenital:

Iatrogenic/foreign:

Pseudonodules (artifact mimics):

Round atelectasis: peripheral, pleura-based mass with "comet tail" sign of vessels and bronchi swirling into it — benign, associated with asbestos exposure.

Long-Term Plan and Secondary Prevention

— Solid nodule stable ≥2 years → benign, stop scans, document in problem list.

— Subsolid nodule stable ≥5 years → benign, stop scans.

— Documented regression → benign (often post-infectious).

— Histologic confirmation of benign etiology → stop surveillance.

— Stage I–II resected: CT chest every 6 months for 2–3 years, then annually.

— Routine PET, brain MRI, bone scan, or tumor markers are not recommended in asymptomatic surveillance.

— Continue at least 5 years, often lifelong given second primary risk.

— Combination pharmacotherapy: varenicline (or bupropion) PLUS nicotine replacement; counseling (5 A's).

— Quitting at any age reduces lung cancer risk; benefit accrues progressively over 10–15 years.

— Document tobacco status at every visit; use motivational interviewing.

— Annual low-dose CT for adults age 50–80 with ≥20 pack-year history who currently smoke or quit within 15 years.

— Use Lung-RADS, not Fleischner, for these patients.

— Stop when patient has not smoked for 15 years or develops health problems limiting life expectancy or willingness for curative surgery.

— Annual influenza, pneumococcal (PCV20 or PCV15+PPSV23), COVID-19, RSV (age ≥60), Tdap, zoster (≥50).

Step 3 management: At every visit during SPN surveillance, address tobacco cessation, lung cancer screening eligibility, and age-appropriate immunizations — these prevention items appear on Step 3 longitudinal care questions as often as the imaging algorithm itself.

End-of-surveillance criteria:

If malignant — post-resection surveillance for NSCLC (per NCCN):

Smoking cessation — single most impactful intervention:

Lung cancer screening for eligible patients (US Preventive Services Task Force 2021):

Vaccinations for patients with chronic lung disease or lung cancer history:

Pulmonary rehabilitation for COPD, post-resection deconditioning.

Environmental: test home for radon (action level ≥4 pCi/L); occupational exposure mitigation.

Follow-Up, Monitoring Parameters, and Patient Counseling

— Provide patient with written follow-up plan including next scan date, location, and contingency if symptoms develop.

— Use EHR-based nodule tracking systems or registry; assign tickler/reminders.

— Size change: ≥2 mm growth in average diameter is significant.

— Attenuation change: new solid component within previously pure GGN → invasive transformation.

— New nodules: changes risk category; may shorten interval.

— Other findings: mediastinal adenopathy, pleural effusion, distant lesions.

— New or worsening cough, hemoptysis, unintended weight loss, persistent chest pain, dyspnea, hoarseness, dysphagia.

— Any new neurologic symptoms (possible CNS metastasis).

— Explain that most nodules are benign — sets appropriate expectations and reduces "scanxiety."

— Discuss radiation dose in lay terms (e.g., "a CT is like a few years of natural background radiation").

— Smoking cessation — every visit, every time.

— Document shared decision-making for surveillance vs biopsy vs observation alternatives.

— Up to 30% of incidental nodules are lost to follow-up.

— Risk factors: uninsured, language barriers, transitions between providers, hospitalization-detected nodules without explicit handoff.

— Mitigation: nurse navigator programs, patient portal reminders, primary care registry oversight.

— Pre-operative for non-pulmonary surgery: incidentally found nodule does NOT routinely delay surgery; coordinate Fleischner follow-up postop unless mass-like or symptomatic.

CCS pearl: When a hospitalized patient is discharged with an incidental nodule, your CCS order set should include: schedule follow-up CT per Fleischner, notify PCP via discharge summary, patient education on red-flag symptoms, and smoking cessation referral — this is the closed-loop transition-of-care expectation.

Imaging cadence — documented schedule:

What to monitor on each follow-up CT:

Symptom monitoring between scans — counsel patient to seek evaluation for:

Patient counseling content:

Adherence challenges:

Special monitoring contexts:

Ethical, Legal, and Patient Safety Considerations

— Failure to communicate an incidental SPN to patient and PCP is a major medico-legal liability and a sentinel patient safety event.

— Best practice: explicit mention in discharge summary, direct communication (call/secure message) to PCP, patient receives written copy with action item, follow-up scan scheduled before discharge when feasible.

— Joint Commission and ACR support "closed-loop" critical/incidental finding communication systems.

— Discuss alternatives — surveillance vs immediate biopsy vs observation without imaging in patients with limited life expectancy.

— Disclose radiation exposure, false-positive cascade, anxiety, and possibility that even surveillance won't fully exclude malignancy.

— Document shared decision-making in chart.

— Specifically discuss pneumothorax risk (~20%), hemorrhage, chest tube possibility, and need for hospital observation.

— Consent should be obtained by the proceduralist, not a surrogate, when feasible.

— Indolent adenocarcinoma in situ (AIS) detected by surveillance may never have caused symptoms or death; aggressive resection has real morbidity.

— Especially relevant in elderly with limited life expectancy — frank discussion of competing risks is ethically required.

— Lung cancer screening uptake is lower in Black, low-income, and rural populations despite higher mortality.

— Bias in pretest probability tools (originally derived in mostly-White cohorts) may under- or over-estimate risk in minorities.

— Active outreach and culturally competent counseling are professional obligations.

— Tuberculosis as cause of nodule → mandatory notification to public health department, contact tracing.

— Occupational exposures (asbestos, silica) — document and counsel on workers' compensation eligibility.

— Every imaging report should explicitly recommend Fleischner-aligned follow-up; PCPs should acknowledge in writing.

Step 3 management: When you discover an incidental nodule on imaging done for another reason during hospitalization, your two non-negotiable actions are: (1) tell the patient and explicitly document the conversation, and (2) ensure PCP receives the finding and follow-up plan in writing — these are tested patient-safety expectations.

Communication of incidental findings (transition-of-care risk):

Informed consent for surveillance:

Informed consent for biopsy:

Overdiagnosis and overtreatment:

Health equity:

Mandatory reporting/public health:

Documentation discipline:

High-Yield Associations and Rapid-Fire Clinical Facts

— <30 days → infection/inflammation.

— 30–400 days → malignancy.

— >450 days → benign.

Board pearl: Memorize the three Fleischner exclusions (age <35, known cancer, immunocompromised) and the screening vs incidental distinction — these gating decisions appear at the front of nearly every SPN Step 3 question stem.

Calcification → benign: central, diffuse, laminated, popcorn (hamartoma).

Calcification → suspicious: eccentric, stippled, amorphous.

Popcorn calcification + fat density = hamartoma (pathognomonic).

Spiculation = "sunburst" or "corona radiata" → highly suspicious for malignancy (LR+ ~5).

Doubling time:

PET false negatives: carcinoid, adenocarcinoma in situ, lesions <8 mm, pure GGN.

PET false positives: granulomas (TB, histo, sarcoid), rheumatoid nodules, abscess.

Doubling time formula: volume doubles when diameter increases by ~26% (1.26×).

Intrapulmonary lymph node: perifissural, triangular/oval, <10 mm, smooth — no follow-up needed.

Pancoast tumor (superior sulcus): shoulder pain, Horner syndrome, T1 nerve root → biopsy first, then chemoradiation, then surgery.

Cavitary nodule wall thickness: >15 mm → malignancy; <4 mm → benign.

Hereditary hemorrhagic telangiectasia (HHT): epistaxis, telangiectasias, pulmonary AVM — risk of paradoxical embolism, stroke, brain abscess.

GPA: multiple cavitary nodules + hematuria + sinusitis + c-ANCA/PR3.

Hamartoma: most common benign lung tumor; 40–60s; popcorn calcification + fat.

Carcinoid: central endobronchial, recurrent pneumonia, hemoptysis; octreotide scan positive, PET often negative.

Stable 2 years (solid) or 5 years (subsolid) = benign, end surveillance.

Fleischner 2017 lower size threshold = 6 mm (was 4 mm in 2005 version).

Lung-RADS, not Fleischner, for lung cancer screening CTs.

Fleischner does not apply to: age <35, known cancer, immunocompromised, screening CT.

Lung cancer screening (USPSTF 2021): age 50–80, ≥20 pack-years, current or quit <15 years.

Board Question Stem Patterns

"A 62-year-old former smoker (30 pack-years, quit 5 years ago) has a 7-mm solid nodule in the right upper lobe on CT obtained for chest pain. No prior imaging available."

→ Answer: Chest CT in 6–12 months (high-risk solid, 6–8 mm).

"A 45-year-old never-smoker has an incidental 4-mm solid nodule on CT."

→ Answer: No routine follow-up.

"A 55-year-old never-smoker has a 9-mm pure ground-glass nodule unchanged from a CT 6 months ago."

→ Answer: Repeat CT in 2 years, continue surveillance until 5 years total.

"A 7-mm solid nodule that was 5 mm one year ago, now spiculated."

→ Answer: PET/CT and/or tissue biopsy — growth + spiculation mandates tissue diagnosis.

"A part-solid nodule with previously 4-mm solid component now 8 mm."

→ Answer: Resection (or biopsy then resection).

"Lobulated 1.5-cm nodule with popcorn calcification and central fat."

→ Answer: Hamartoma — no further workup.

"Patient enrolled in low-dose CT lung cancer screening has 6-mm solid nodule."

→ Answer: Apply Lung-RADS, NOT Fleischner.

"Patient with breast cancer 2 years prior has a new 1-cm lung nodule."

→ Answer: PET/CT and tissue biopsy — not Fleischner.

"HIV patient with CD4 50 and new 1.5-cm cavitary nodule."

→ Answer: Bronchoscopy with BAL — infectious workup, not Fleischner.

"4-mm solid nodule unchanged on CTs from 3 years ago and 2 years ago."

→ Answer: Benign — no further surveillance.

"Patient discharged with incidental SPN noted in radiology report but not mentioned in discharge summary."

→ Answer: Best preventive measure = closed-loop incidental finding communication system / EHR registry.

Key distinction: Step 3 prefers stems that embed Fleischner inside a discharge or outpatient transition-of-care scenario — the right answer often involves communication and follow-up scheduling as much as the imaging interval itself.

Stem 1 — Classic incidental solid nodule:

Stem 2 — Sub-6 mm low-risk solid:

Stem 3 — Persistent pure GGN:

Stem 4 — Growing nodule:

Stem 5 — Part-solid with growing solid component:

Stem 6 — Calcification pattern:

Stem 7 — Wrong-algorithm trap:

Stem 8 — Known malignancy:

Stem 9 — Immunocompromised:

Stem 10 — Stability:

Stem 11 — Communication failure:

One-Line Recap

For an incidental pulmonary nodule in an adult ≥35 without known cancer or immunocompromise, apply Fleischner 2017: stratify by size (cutoff 6 mm), attenuation (solid vs subsolid), number, and clinical risk to determine whether to observe, surveil with serial low-dose CT (2 years for solid, 5 years for subsolid), or pursue PET/biopsy/resection for nodules >8 mm, growing nodules, or part-solid nodules with ≥6 mm solid components.

— Gate first, algorithm second: confirm patient is ≥35, not in a screening program, no known cancer, not immunocompromised — otherwise Fleischner does NOT apply (use Lung-RADS, oncologic surveillance, or infectious workup instead).

— Solid ≥8 mm or any growing nodule: consider PET/CT, tissue biopsy, or surgical resection — Mayo/Brock probability and patient surgical candidacy guide choice.

— Subsolid nodules need longer (5-year) surveillance; PET is unreliable; development of a solid component triggers resection because it signals invasive transformation along the adenocarcinoma spectrum.

— The "softer" Step 3 layer: smoking cessation at every visit, closed-loop communication of incidental findings to patient and PCP, shared decision-making about radiation/anxiety/overdiagnosis especially in the elderly, and recognizing lung-cancer screening eligibility (age 50–80, ≥20 pack-years, current or quit within 15 years).

Board pearl: If the question gives you size, attenuation, risk factors, and a prior scan, do four things in order: (1) confirm Fleischner applies, (2) categorize the nodule, (3) check for growth or new solid component, (4) match to the surveillance interval or escalate to PET/biopsy/resection — and always pair the imaging answer with smoking cessation and explicit follow-up communication for full Step 3 credit.

Quick recap bullets: